All In Biotech

NDA 215358 · Novartis

Scemblix

Asciminib Hydrochloride · Oral

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, Oct 29, 2021: To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Oct 29, 2021

Approved uses

7

Original approval plus efficacy supplements

Registered trials

44

6 Phase 3, 16 recruiting

FAERS reports

3,492

2,282 serious, 390 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 22, 2026.

SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Previously treated Ph+ CML in CP. ( 1 ) Ph+ CML in CP with the T315I mutation. ( 1 )

Mechanism: Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by binding to the ABL myristoyl pocket. In studies conducted in vitro or in animal models of CML, asciminib showed activity against wild-type BCR::ABL1 and several mutant forms of the kinase, including the T315I mutation.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 25, 2025 Supplement 12 · Efficacy OrphanLetterLetterLabel
  • Oct 2, 2025 Supplement 10 · Efficacy OrphanLabelLetter
  • Oct 29, 2024 Supplement 8 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Oct 29, 2024 Supplement 9 · Efficacy · priority review OrphanLetterLabel
  • Oct 12, 2022 Supplement 1 · Efficacy · priority review OrphanLetterLabel
  • Oct 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetter
  • Oct 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
  • SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 40MG BASE · TABLET, ORAL · Prescription
  • SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
  • SCEMBLIX · ASCIMINIB HYDROCHLORIDE EQ 20MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Asciminib" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue265
  • death201
  • nausea185
  • drug ineffective179
  • thrombocytopenia171
  • drug intolerance141
  • headache141
  • diarrhoea138
  • rash110
  • pleural effusion109
  • hypertension106
  • arthralgia104

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20183
201914
202022
202133
2022412
2023556
2024716
2025934
2026801

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Scemblix (Asciminib Hydrochloride)

2024 spending

$197M

Beneficiaries

1,314

8,072 claims

Per beneficiary

$150,066

$351.22 per unit

View as table
YearSpending
2020$0
2021$2,112,304
2022$52,486,018
2023$114,488,117
2024$197,186,980

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.